Molecular Genetic Analysis of the Interleukin 6 and Tumor Necrosis Factor α Gene Polymorphisms in Multiple Myeloma

Molecular Biology

Volumn 37, Issue 3, 2003, Pages 358-361

  Yakupova, E V ^a   Grinchuk, O V ^a   Kalimullina, D Kh ^b   Bakirov, B A ^b   Galimova, R R ^b   Makarova, O V ^a   Khusnutdinova, E K ^a   Viktorova, T V ^a  

^a INSTITUTE OF BIOCHEMISTRY AND GENETICS   (Russian Federation)

^b Ufa Institute of Occupational Medicine and Human Ecology   (Russian Federation)

Author keywords

Allele; Genotype; Interleukin 6; Multiple myeloma; Polymorphism; Tumor necrosis factor

Indexed keywords

INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALLELE; ARTICLE; BENIGN TUMOR; CANCER CLASSIFICATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR GENETICS; MULTIPLE MYELOMA; PROMOTER REGION; PROTEIN EXPRESSION;

EID: 0038463741     PISSN: 00268933     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024227008451     Document Type: Article

References (23)

1. Kruglova G.V., Votyakova O.M. 2000. Khimioterapiya opukholevykh zabolevanii (Chemotherapy of Tumors). Moscow.
2. Lichtenstain A., Tu Y., Fadu C., Vesior R., Berenson J. 1995. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol. 162, 248-255.
3. Roitt I., Brostoff J., Male D. 2000. Immunologiya (Immunology). Moscow: Mir.
4. Hallek M., Bergsagel P.L., Anderson K.C. 1998. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 91, 3-21.
5. Fayad L., Keating M.J., Reuben J.M. et al. 2001. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 97, 256-263.
6. Hardin J., MacLeod S., Grigorieva I. et al. 1994. Interleukin-6 prevents dexametasone-induced myeloma cell death. Blood. 84, 3063-3070.
7. Nachbaur D.M., Herold M., Maneschg A., Huber A. 1991. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Annu. Hematol. 62, 54-58.
8. Serebryanaya N.B., Voloshin S.V., Shamanskii S.V., Zhiburt E.B. 2001. Diagnostika i lechenie limfom (Diagnosis and Treatment of Lymphomas). St. Petersburg. 318-319.
9. Salles G., Bienvenu J., Bastion Y., Barbier Y., Doche C., Warzocha K., Gutowski M.C., Rieux C., Coiffier B. 1996. Elevated circulating levels of TNFα and its p55 soluble receptor are associated with an adverse prognosis in lymphoma patients. Br. J. Hematology. 93, 352-359.
10. Andreeva N.E. 1998. Diagnostika i lechenie mnozhestvennoi mielomy (Diagnosis and Treatment of Multiple Myeloma). Moscow: Newdiamed.
11. Mathew C.C. 1984. The isolation of high molecular weight eucariotic DNA. Meth. Mol. Biol. L.: Human Press, 2, 31-34.
12. Fernández-Real J.M., Broch M., Vendrell J. et al. 2000. Interleukin-6 gene polymorphism and lipid anomalities in healthy subjects. J. Clin. Endocrinol. Metab. 85, 1334-1339.
13. Fishman D., Faulds G., Jeffery R. et al. 1998. The effect of novel polymorphisms in the interleukin-6 on IL-6 transcription and plasma levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. 102, 1369-1376.
14. Stuber F., Udalova I.A., Book M., Drutskaya L.N., Kuprash D. V. et al. 1995-96. -308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human TNF promoter. J. Inflamm. 46(1), 42-50.
15. Day C.P., Grove J., Daly A.K. et al. 1998. Tumor necrosis factor-alpha gene promoter polymorphism and decreased insulin resistance. Diabetologia. 41, 430-434.
16. Zhivotovsky L.A. 1991. Populyatsionnaya biometriya (Population Biometrics). Moscow: Nauka.
17. 2 and problem of small samples. Mol. Biol. Evol. 6, 539-545.
18. Liu Y., Bernard H.U., Apt D. 1997. NFI-B3, a novel transcriptional repressor of the nuclear factor I family, is generated by alternative RNA processing. J. Biol. Chem. 272, 10739-10745.
19. Wilson A.G., Symons J.A., McDowell T.L. et al. 1997. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc. Natl. Acad. Sci. USA. 94, 3195-3199.
20. Messer G., Spengler U., Jung M.C. et al. 1991. Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J. Exp. Med. 173, 209-219.
21. Davies F.E., Rollinson S.J., Rawstron A.C. et al. 2000. High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment. J. Clinic. Oncol. 18, 2843-2851.
22. Neben K., Mytilineos J., Moehler T.M., Preiss A. et. al. 2002. Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood. 100, 2263-2265.
23. Zheng C., Huang D., Bergenbrant S., Sundblad A. et. al. 2000. Interleukin 6, tumor necrosis factor α, interleukin 1β and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br. J. Haematol. 109, 39-45.